-
Press Release
2019/11/13
Abnova Integrates CARlike-IL12 Technology and Setup a IL-12 Patent Portfolio Strategy for Gene Modified T cell Therapy
-
Conference
2019/11/08
Invited Talk at En Chu Kong Hospital
-
Press Release
2019/10/29
Abnova’s mutaFISH™ Probes Energize the Fluorescent In Situ Hybridization Global Market and Propel New Precision Medicine Applications
-
Conference
2019/10/28
がん研究ツール最前線 2019
-
Conference
2019/10/11
第 9 回がん新薬開発合同シンポジウム がん治療の未来戦略
-
Press Release
2019/09/23
Abnova Subsidiary Wellconn Genomics™ Clinical Laboratory Introduces Germline Genetic Testing Service for Prostate Cancer Hereditary Predisposing Genes
-
Press Release
2019/08/26
Abnova Completes GMP Manufacturing Agreements and Appoints Aldevron and Lentigen to Manufacture the Respective Transfer Plasmid and Lentiviral Vector for its Gene-Modified T Cell Therapy Clinical Trials
-
Press Release
2019/05/28
Abnova & National Cancer Center Hospital East Japan Collaborate to Setup Decentralized, Point-of-Care, IL-12 Gene Modified T Cell Manufacturing for Cancer Therapy
-
Press Release
2019/05/06
Abnova Introduces LiquidCell™ Negative Enrichment Circulating Tumor Cell Platform for the Clinical Pathology Market
-
Press Release
2019/03/18
Abnova Expands its Patent Repertoire of T Cell Therapy Against Solid Tumors